Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
XenoPort, Inc. Announces Pricing of Public Offering of Common Stock
XenoPort, Inc. announced the pricing of an underwritten offering of 6,153,846 shares of its common stock at a price to the public of $6.50 per share. XenoPort has granted to the underwriters a 30-day option to purchase up to an additional 923,076 shares of its common stock. All of the shares in the offering are being offered by XenoPort. The offering is expected to close on or about July 30, 2012. Credit Suisse Securities (USA) LLC is acting as sole book-running manager for the offering. RBC Capital Markets, LLC is acting as co-manager for the offering. A registration statement relating to the shares described above was previously filed with, and has been declared effective by, the Securities and Exchange Commission (SEC).
Latest Developments for Xenoport Inc
- XenoPort Inc Announces Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients
- Glaxosmithkline Plc And XenoPort, Inc. Receive FDA Approval For Horizant For Postherpetic Neuralgia
- XenoPort, Inc. Announces XP21279 Phase 2 Clinical Trial Results in Patients With Advanced Parkinson`s Disease
Latest Key Developments in Biotechnology
- Intercept Pharmaceuticals Inc Announces Pricing Of Public Offering Of Common Stock
- UCLA Presents Data on Medicinova Inc's MN-166 in Methamphetamine Addiction
- bluebird bio Inc Announces Pricing Of Initial Public Offering
- iCo Therapeutics Inc Updates On iDEAL Phase 2 Study For Treatment Of Diabetic Macular Edema
- Share this
- Link this
- Digg this


Follow Reuters